Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

What Happened: A notable Form 4 filing on Monday with the U.S. Securities and Exchange Commission revealed that Meury, Chief Executive Officer at Incyte, exercised stock options for 0 shares of INCY, ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

Mesoblast (NASDAQ:MESO – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

The medicinal cannabis purveyor Bioxyne was the top performing ASX biotech in 2024-25, recording a 300% share gain. ... Read ...

The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) ...

Ten Cap Co-Founder and Lead Portfolio Manager Jun Bei Lu speaks on Bloomberg TV about the challenges facing equity investors ...